S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Critical asset just had biggest fall on record (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
The former chairman of the state-owned Bank of Beijing is being investigated for alleged corruption
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Arkhouse and Brigade up Macy's takeover offer to $6.6 billion following rejection of previous deal
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
OPEC+ production cuts deepen with extensions from Saudi Arabia, Russia and other oil giants
South Korea takes steps to suspend licenses of striking doctors after they refuse to end walkouts

Arvinas (ARVN) Stock Price, News & Analysis

$47.30
+1.32 (+2.87%)
(As of 03/1/2024 ET)
Today's Range
$46.51
$51.51
50-Day Range
$36.38
$52.31
52-Week Range
$13.57
$53.08
Volume
1.02 million shs
Average Volume
849,859 shs
Market Capitalization
$3.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.93

Arvinas MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
26.7% Upside
$59.93 Price Target
Short Interest
Bearish
17.05% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Arvinas in the last 14 days
Based on 62 Articles This Week
Insider Trading
Selling Shares
$404,489 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.15) to ($5.40) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.13 out of 5 stars

Medical Sector

395th out of 947 stocks

Pharmaceutical Preparations Industry

181st out of 439 stocks


ARVN stock logo

About Arvinas Stock (NASDAQ:ARVN)

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Stock Price History

ARVN Stock News Headlines

Arvinas' (ARVN) Buy Rating Reiterated at HC Wainwright
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Arvinas (NASDAQ:ARVN) Rating Reiterated by Oppenheimer
Arvinas (NASDAQ:ARVN) Price Target Raised to $90.00
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Arvinas (NASDAQ:ARVN) Trading 5.6% Higher on Analyst Upgrade
Arvinas (NASDAQ:ARVN) PT Raised to $59.00 at Wedbush
Ronald Peck Sells 1,699 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock
Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)
Navigating 7 Analyst Ratings For Arvinas
Arvinas: Q4 Earnings Insights
See More Headlines
Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
3/03/2024
Next Earnings (Estimated)
5/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
415
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.93
High Stock Price Target
$90.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+26.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-185.09%
Pretax Margin
-463.57%

Debt

Sales & Book Value

Annual Sales
$78.50 million
Book Value
$9.69 per share

Miscellaneous

Free Float
66,348,000
Market Cap
$3.22 billion
Optionable
Optionable
Beta
1.95
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. John G. Houston Ph.D. (Age 64)
    Chairperson, CEO & President
    Comp: $1.08M
  • Mr. Sean A. Cassidy CPAMr. Sean A. Cassidy CPA (Age 54)
    M.B.A., CFO, Principal Financial Officer & Treasurer
    Comp: $683k
  • Dr. Ian Taylor Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $692k
  • Dr. Ronald A. Peck M.D. (Age 58)
    Chief Medical Officer
    Comp: $701.63k
  • Mr. David K. Loomis M.B.A. (Age 50)
    VP, Principal Accounting Officer & Chief Accounting Officer
  • Mr. Jeff Boyle
    Vice President of Investor Relations
  • Mr. Jared M. Freedberg J.D. (Age 55)
    General Counsel
  • Dr. Randy Teel Ph.D. (Age 45)
    Senior Vice President of Corporate & Business Development
  • Mr. Steve Weiss (Age 54)
    Senior VP & Chief Human Resources Officer
  • Dr. John A. Grosso Ph.D. (Age 67)
    Senior Vice President of R&D Technical Operations














ARVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price target for 2024?

16 Wall Street research analysts have issued twelve-month price targets for Arvinas' shares. Their ARVN share price targets range from $20.00 to $90.00. On average, they predict the company's share price to reach $59.93 in the next twelve months. This suggests a possible upside of 26.7% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2024?

Arvinas' stock was trading at $41.16 at the start of the year. Since then, ARVN shares have increased by 14.9% and is now trading at $47.30.
View the best growth stocks for 2024 here
.

Are investors shorting Arvinas?

Arvinas saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 7,770,000 shares, an increase of 19.5% from the January 31st total of 6,500,000 shares. Based on an average daily volume of 875,900 shares, the days-to-cover ratio is presently 8.9 days. Currently, 17.1% of the shares of the company are sold short.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Tuesday, February, 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by $1.38. The firm had revenue of ($43.10) million for the quarter, compared to analysts' expectations of $38.91 million. Arvinas had a negative net margin of 185.09% and a negative trailing twelve-month return on equity of 70.24%. During the same quarter in the previous year, the business posted ($1.56) earnings per share.

What ETFs hold Arvinas' stock?
What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Who are Arvinas' major shareholders?

Arvinas' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.82%), RTW Investments LP (7.66%), Price T Rowe Associates Inc. MD (6.96%), Price T Rowe Associates Inc. MD (6.96%), Avidity Partners Management LP (5.42%) and Bellevue Group AG (4.56%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARVN) was last updated on 3/3/2024 by MarketBeat.com Staff